Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Wesana Health
Deal Size : Undisclosed
Deal Type : Acquisition
Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health
Details : Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental healt...
Brand Name : SANA-013
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : Psilocybine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Wesana Health
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?